Chief Technical Officer and Director
Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years. In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.
Chief Executive Officer and Director
Thomas D’Orazio has served as Chief Executive Officer and President of ImmunoPrecise since August 28, 2016. Mr. D’Orazio is an experienced business executive with over 25 years in the life sciences and pharmaceutical industries where he has a successful track record building teams to develop and implement strategic growth plans. Mr. D’Orazio has worked for notable industry companies such as such as Pfizer, Merck and QLT. Mr. D’Orazio is also an entrepreneur who has founded or co-founded multiple life-sciences related companies. Mr. D’Orazio has a A.B. in Chemistry from Loyola University of Chicago and an MBA from Vanderbilt University.
Chief Scientific Officer
Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for prioritization of research projects, alignment with corporate strategy and developing new product introductions. She received her B.Sc. in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.
Head of Laboratory Services
Teri Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a fulltime employee upon graduation in 2000. She began as a technician and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering capabilities, particularly in the area of mouse hybridomas. Ms. Otto holds a B.Sc. (with distinction) from University of Victoria in Microbiology and Associate Degrees in Psychology, Bio Chemistry, and Applied Chemistry from Camosum College in Victoria, BC.
Vice President of Corporate Services
Dr. Kevin Wong has served as President of ImmunoPrecise and Vice President of Corporate Services since joining the company in 2013. Dr. Wong has previous experience working in both industry and academic settings. He managed the laboratory operations for Protox Therapeutics for nine years prior to joining ImmunoPrecise. Dr. Wong spent six years at Cambridge University as a Research Associate in both the Departments of Biochemistry and Pathology, as well as two years as a Research Associate at University of Ottawa Department of Cellular and Molecular Medicine. Dr. Wong graduated from the University of Victoria with a Ph.D. in Biochemistry. Dr. Wong has been published in more than a dozen peer-reviewed articles in journals of biological sciences.